Farewell to growth stocks, market access and low valuations of blue-chip turns up, many funds off guard. Harvest Fund stressed in the Outlook for the quarter 2010 report to growth-oriented, so still Super distribution bio-pharmaceutical industry. China universal its dedicated medical unit of tianfu pharmaceutical makes its configuration in the pharmaceutical industry is well more than average. Great wall of Super Fund to the pharmaceutical, biotechnology proportions is ranked first.
Recommended reading
· fengji logic Investment Bank unit fund management fee or by performance received enhanced means base performance than pure means base electric branch homes break Wang yawei high playing new into mystery Guangzhou country light will increased lifted Bo Shi Fund floating losses Fund increased distribution food and wholesale retail private continuous five months run lost market national day Xin months site revealing three quarter layout opportunity just super distribution and no brings on net of contribution, instead for fund company brings has loss, despite the home Fund on medicine biological industry has reduction, but Super distribution Xia loss cannot avoid. Harvest overweight hengrui medicine (600,276, unit), share prices fell in the first quarter 23% quarter, prospects for harvest Fund for the first quarter of 2011, is dominated by growth stocks.
This is corresponding to the first quarter of 2011 and harvest Fund for medicine unit of super distribution. Harvest Fund for pharmaceutical, biotechnology industry, and more than the industry average.
Stock market for pharmaceutical, biotechnology industry standard 3.48%, harvest Fund 8.02% allocation on top of it. However, super distribution pharmaceutical, biotechnology industry does not bring any benefits to harvest the net growth of the Fund.
Pharmaceutical, biotechnology in the first quarter on net harvest Fund contribution rate is-0.6%. A negative net contribution rate is on the back of pharmaceutical, biotechnology industry on the a-shares do not give the performance of the force, poor 2010 rising in the same day.
As of March 31, 2011, the industry index price-6.48% in the pharmaceutical sector, medical unit for a long time a floating green.
In harvest Fund in its 24 funds, there are 7 funds for pharmaceutical, biotechnology industry interests, significantly more than the industry average on preference of pharmaceutical, biotechnology. Harvest growth allocation in the pharmaceutical sector is 20.5%, harvest growth 27.37%, harvest strategy growth (070011, Fund) for 23.48%, harvest research collection (070013, Fund) for 10.9%, harvest returns flexible configuration of 10.62%, harvest quality enterprises (070099, Fund) for 20.84%, funds and 12.07%.
Fund managers of these funds are on different management.
In Ka real Fund heavy warehouse of Qian ten a unit in the, medicine biological industry of stock was Fu medicine (600,079, unit 's), and renhe drug industry (000650, unit 's), and river Chinese medicine industry (600,750, unit 's), and guoyao shares (600,511, unit 's), and Dong-e e-Donkey-hide gelatin (000423, unit 's), and consistent drug industry (000028, unit 's), and constant Swiss medicine, and sea Cheung drug industry (002099, unit 's), and Yunnan baiyao (000538, unit 's), and kelun drug industry (002422, unit 's) and China State pharmaceutical (002004, unit 's).
However, some stocks shares about good falls all the way, although harvest Fund in reduction of a large number of people in the first quarter good medicine, Dong-e e-Jiao, and Yunnan baiyao, but other drug unit had been overweight, hengrui medicine, where an increase of 6 million units of configuration. Persons were four Fund warehouse at Fuk medicine from highest price 29.8 yuan per unit on November 25, 2010 had a free fall after, as of May 12, 2011 closing price of only $ 22.51/unit.
Hengrui medicine is of overweight 6 million shares from $ 64.28/unit line dropped to only $/unit. Westlands, China universal to reduce biological Westlands, Miss the dropped China Universal Fund to reduce biological (002007, unit) not as shares fell at a rate of speed.
5.97 million shares, although the first quarter of 2011 the company to reduce, hualan bio holdings number are still among the best in all stocks, ranked sixth, 41.69 million shares. Super distribution Westlands bio is hualan bio on the back of falling share prices, from the high $ 59.51/unit drops to $/unit.
More than 74% stock price had just experienced a quarter of the time. In the pharmaceutical, biotechnology industry China universal fund losses small, pharmaceutical, biotechnology industry in the first quarter for the contribution of the funds is-4.25%.
Apart from configuration China Blue biological, meeting added rich fund its Fund also configuration has ConMed drug industry (600,518, unit 's), and people Fu medicine, and river Chinese medicine industry, and Dong-e e-Donkey-hide gelatin, and Yunnan baiyao, and tongrentang (600,085, unit 's), and diving medical (002223, unit 's), and double Heron drug industry (002038, unit 's), and Yi Bai pharmaceutical (600,594, unit 's), and renhe drug industry and morning biological (300,138, unit 's). Super proportions to bio-medicine industry China Universal Fund ranked first, second.
Relative to the average market 3.48%, China universal mixed Fund on bio-medicine industry 11.74%. However, if you look at China universal under each Fund for bio-pharmaceutical industry-only configuration, you can find the actual allocation of each Fund to the pharmaceutical, biotechnology industry average deviated from the market level is not high, about off the 2% per cent. Configuration deviation of the key factors affecting their industry is owned by China universal has a fund specially equipped medical unit, China universal healthcare.
Relative to the industry average of 3%, its allocation to the pharmaceutical, biotechnology is 82.5%. InAll were in the warehouse in bio-medicine unit, only hualan bio, ConMed pharmacy, Yunnan baiyao Fund by two to four positions, others have only been a Fund and cartridge. In stocks, ConMed renhe pharmaceutical and medicine industry, the Dong-e e-Jiao, chenguang biological are overweight, contrast with that, however, is constantly falls in share prices. Fund medical configuration deviation from most of the great wall the first quarter of 2011, allocation to pharmaceutical, biotechnology industry, and industry average deviation from the biggest fund companies, non-Fund MO is the great wall. In the first quarter, the great wall on the funds in the pharmaceutical, biotechnology industry against standard industrial configuration for 19.87%.
Ranked first. However, no suspense is lost.
With the pharmaceutical, biotechnology industry in the first quarter of the overall float green, great wall Fund cannot avoid loss, contribution to the pharmaceutical, biotechnology industry on the net value of the company also is a negative number, is-1.63%. Funds in the pharmaceutical industry to the great wall in the warehouse stock was Harbin pharmaceutical shares (600,664 shares) and the double-crane pharmaceutical industry (600,062, unit), Harbin pharmaceutical holding is 25.55 million shares to the quantity of shares, relative to the four quarters of 2010, the reduction of 2.33 million shares. Double-crane pharmaceutical industry as 19.71 million units, relative to the four quarters of 2010, overweight 460,000 shares.
-Holding ranking of 11 and 14 respectively in volume. However, notwithstanding the reduction of overweight there, unchanged is two shares the same all the way to go down. Double-crane pharmaceutical industry from the high $ 34.8/unit per cent to $/unit.
Harbin pharmaceutical shares also fell all the way from $ 27.6 unit. In addition, the great wall Fund or heavy cartridge Shanghai pharmaceutical (601,607, unit), Heng Shui Fu, medicine, medicine, people in the drug industry (600,329, unit), but the invariant is still slumping stock price.